|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.3869 - 0.4085|
|52 Week Range||0.2200 - 1.0000|
|Beta (5Y Monthly)||1.90|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Complements previously published data that cites Lexaria's TurboCBD to demonstrate a significant 5% reduction in mean arterial blood pressure KELOWNA, BC / ACCESSWIRE / July 28, 2020 / Lexaria Bioscience Corp.
KELOWNA, BC / ACCESSWIRE / July 21, 2020 / Lexaria Bioscience Corp.
KELOWNA, BC / ACCESSWIRE / July 16, 2020 / Lexaria Bioscience Corp. (LXRP) (LXX.CN) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms, announces that Phase I of the research and development program of oral forms of nicotine delivery utilizing Lexaria's patented DehydraTECHTM technology with Altria Ventures Inc. ("Altria") has concluded. The Phase I research and development program was initiated to evaluate reduced health risks relative to combusted tobacco of a preliminary DehydraTECHTM oral nicotine formulation that Lexaria had previously announced findings with in 2018.